- Browse by Author
Browsing by Author "McCracken, James"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Association Between Residential Greenness and Cardiovascular Disease Risk(Wiley, 2018-12-05) Yeager, Ray; Riggs, Daniel W.; DeJarnett, Natasha; Tollerud, David J.; Wilson, Jeffrey S.; Conklin, Daniel J.; O'Toole, Timothy E.; McCracken, James; Lorkiewicz, Pawel; Xie, Zhengzhi; Zafar, Nagma; Krishnasamy, Sathya S.; Srivastava, Sanjay; Finch, Jordan; Keith, Rachel J.; DeFilippis, Andrew; Rai, Shesh N.; Liu, Gilbert; Bhatnagar, Aruni; Department of Geography, School of Liberal ArtsBackground Exposure to green vegetation has been linked to positive health, but the pathophysiological processes affected by exposure to vegetation remain unclear. To study the relationship between greenness and cardiovascular disease, we examined the association between residential greenness and biomarkers of cardiovascular injury and disease risk in susceptible individuals. Methods and Results In this cross‐sectional study of 408 individuals recruited from a preventive cardiology clinic, we measured biomarkers of cardiovascular injury and risk in participant blood and urine. We estimated greenness from satellite‐derived normalized difference vegetation index (NDVI) in zones with radii of 250 m and 1 km surrounding the participants’ residences. We used generalized estimating equations to examine associations between greenness and cardiovascular disease biomarkers. We adjusted for residential clustering, demographic, clinical, and environmental variables. In fully adjusted models, contemporaneous NDVI within 250 m of participant residence was inversely associated with urinary levels of epinephrine (−6.9%; 95% confidence interval, −11.5, −2.0/0.1 NDVI) and F2‐isoprostane (−9.0%; 95% confidence interval, −15.1, −2.5/0.1 NDVI). We found stronger associations between NDVI and urinary epinephrine in women, those not on β‐blockers, and those who had not previously experienced a myocardial infarction. Of the 15 subtypes of circulating angiogenic cells examined, 11 were inversely associated (8.0–15.6% decrease/0.1 NDVI), whereas 2 were positively associated (37.6–45.8% increase/0.1 NDVI) with contemporaneous NDVI. Conclusions Independent of age, sex, race, smoking status, neighborhood deprivation, statin use, and roadway exposure, residential greenness is associated with lower levels of sympathetic activation, reduced oxidative stress, and higher angiogenic capacity.Item Association Between Residential Greenness and Cardiovascular Disease Risk(American Heart Association, 2018-12-18) Yeager, Ray; Riggs, Daniel W.; DeJarnett, Natasha; Tollerud, David J.; Wilson, Jeffrey S.; Conklin, Daniel J.; O'Toole, Timothy E.; McCracken, James; Lorkiewicz, Pawel; Xie, Zhengzhi; Zafar, Nagma; Krishnasamy, Sathya S.; Srivastava, Sanjay; Finch, Jordan; Keith, Rachel J.; DeFilippis, Andrew; Rai, Shesh N.; Liu, Gilbert; Bhatnagar, Aruni; Geography, School of Liberal ArtsBackground Exposure to green vegetation has been linked to positive health, but the pathophysiological processes affected by exposure to vegetation remain unclear. To study the relationship between greenness and cardiovascular disease, we examined the association between residential greenness and biomarkers of cardiovascular injury and disease risk in susceptible individuals. Methods and Results In this cross-sectional study of 408 individuals recruited from a preventive cardiology clinic, we measured biomarkers of cardiovascular injury and risk in participant blood and urine. We estimated greenness from satellite-derived normalized difference vegetation index ( NDVI ) in zones with radii of 250 m and 1 km surrounding the participants' residences. We used generalized estimating equations to examine associations between greenness and cardiovascular disease biomarkers. We adjusted for residential clustering, demographic, clinical, and environmental variables. In fully adjusted models, contemporaneous NDVI within 250 m of participant residence was inversely associated with urinary levels of epinephrine (-6.9%; 95% confidence interval, -11.5, -2.0/0.1 NDVI ) and F2-isoprostane (-9.0%; 95% confidence interval, -15.1, -2.5/0.1 NDVI ). We found stronger associations between NDVI and urinary epinephrine in women, those not on β-blockers, and those who had not previously experienced a myocardial infarction. Of the 15 subtypes of circulating angiogenic cells examined, 11 were inversely associated (8.0-15.6% decrease/0.1 NDVI ), whereas 2 were positively associated (37.6-45.8% increase/0.1 NDVI ) with contemporaneous NDVI . Conclusions Independent of age, sex, race, smoking status, neighborhood deprivation, statin use, and roadway exposure, residential greenness is associated with lower levels of sympathetic activation, reduced oxidative stress, and higher angiogenic capacity.Item Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial(Mary Ann Liebert, Inc., 2015-08-01) Aman, Michael; Rettiganti, Mallikarjuna; Nagaraja, Haikady N.; Hollway, Jill A.; McCracken, James; McDougle, Christopher J.; Tierney, Elaine; Scahill, Lawrence; Arnold, L. Eugene; Hellings, Jessica; Posey, David J.; Swiezy, Naomi B.; Guhman, Jaswinder; Grados, Marco; Shah, Bhavik; Vitiello, Benedetto; Department of Psychiatry, IU School of MedicineOBJECTIVE: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1-2 year follow-up period. METHODS: In a naturalistic study, 84 children and adolescents 5-17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy. RESULTS: Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow-up. Several other measures of maladaptive behavior (some related to socialization) also showed improved functioning in association with risperidone on the ABC or on the Modified Real Life Rating Scale. CONCLUSIONS: Increased appetite, weight gain, and enuresis are risks associated with long-term risperidone. Our data suggest that these risks were balanced by longer-term behavioral and social benefits for many children over 1.8 years of ongoing treatment.